Literature DB >> 11214906

A detailed analysis of the MECP2 gene: prevalence of recurrent mutations and gross DNA rearrangements in Rett syndrome patients.

V Bourdon1, C Philippe, O Labrune, D Amsallem, C Arnould, P Jonveaux.   

Abstract

Mutations in the X-linked methyl-CpG-binding protein 2 gene (MECP2) have been found to be a cause of Rett syndrome (RTT). In order to provide further insights into the distribution and the spectrum of mutations, we investigated, in addition to the whole coding sequence, a phylogenetically conserved sequence within the 3' untranslated region (3' UTR) of the MECP2 gene for 55 sporadic RTT, including 47 typical and 8 nonclassical cases. We have developed an approach based on conformation-sensitive gel electrophoresis, sequence analysis and, for the first time, Southern blot analysis. Mutation detection, including unreported gross DNA rearrangements, was achieved in 79% of classical RTT and 25% of nonclassical RTT patients. The high prevalence of recurrent mutations allows us to propose a molecular diagnosis strategy for RTT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11214906     DOI: 10.1007/s004390000422

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

Review 1.  Rett syndrome and MeCP2: linking epigenetics and neuronal function.

Authors:  Mona D Shahbazian; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2002-11-19       Impact factor: 11.025

2.  A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome.

Authors:  Sabine M Klauck; Susan Lindsay; Kim S Beyer; Miranda Splitt; John Burn; Annemarie Poustka
Journal:  Am J Hum Genet       Date:  2002-02-15       Impact factor: 11.025

3.  Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients.

Authors:  H L Archer; S D Whatley; J C Evans; D Ravine; P Huppke; A Kerr; D Bunyan; B Kerr; E Sweeney; S J Davies; W Reardon; J Horn; K D MacDermot; R A Smith; A Magee; A Donaldson; Y Crow; G Hermon; Z Miedzybrodzka; D N Cooper; L Lazarou; R Butler; J Sampson; D T Pilz; F Laccone; A J Clarke
Journal:  J Med Genet       Date:  2005-09-23       Impact factor: 6.318

4.  Mutation analysis of the MECP2 gene in patients of Slavic origin with Rett syndrome: novel mutations and polymorphisms.

Authors:  Daniela Zahorakova; Robert Rosipal; Jan Hadac; Alena Zumrova; Vladimir Bzduch; Nadezda Misovicova; Alice Baxova; Jiri Zeman; Pavel Martasek
Journal:  J Hum Genet       Date:  2007-02-15       Impact factor: 3.172

5.  Alternative polyadenylation of MeCP2: Influence of cis-acting elements and trans-acting factors.

Authors:  Catherine M Newnham; Tyra Hall-Pogar; Songchun Liang; Jing Wu; Bin Tian; Jim Hu; Carol S Lutz
Journal:  RNA Biol       Date:  2010-05-16       Impact factor: 4.652

6.  Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.

Authors:  Jiong Tao; Hilde Van Esch; M Hagedorn-Greiwe; Kirsten Hoffmann; Bettina Moser; Martine Raynaud; Jürgen Sperner; Jean-Pierre Fryns; Eberhard Schwinger; Jozef Gécz; Hans-Hilger Ropers; Vera M Kalscheuer
Journal:  Am J Hum Genet       Date:  2004-12       Impact factor: 11.025

7.  Rett Syndrome.

Authors:  E E J Smeets; K Pelc; B Dan
Journal:  Mol Syndromol       Date:  2012-04-16

8.  MECP2 mutations or polymorphisms in mentally retarded boys: diagnostic implications.

Authors:  Violaine Bourdon; Christophe Philippe; Dominique Martin; Alain Verloès; Agnès Grandemenge; Philippe Jonveaux
Journal:  Mol Diagn       Date:  2003

9.  De novo deletion in MECP2 in a monozygotic twin pair: a case report.

Authors:  Kirti Mittal; Madhulika Kabra; Ramesh Juyal; Thelma BK
Journal:  BMC Med Genet       Date:  2011-08-27       Impact factor: 2.103

10.  Xq28 (MECP2) microdeletions are common in mutation-negative females with Rett syndrome and cause mild subtypes of the disease.

Authors:  Ivan Y Iourov; Svetlana G Vorsanova; Victoria Y Voinova; Oxana S Kurinnaia; Maria A Zelenova; Irina A Demidova; Yuri B Yurov
Journal:  Mol Cytogenet       Date:  2013-11-27       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.